Preclinical research using MultiStem cells has shown Multipotent Adult Progenitor Cells, or MAPC®, may be beneficial in the treatment of a variety of critical care and difficult to treat inflammatory…
Read More »Athersys
Dr. Richard Perry, Consultant Neurologist at the National Hospital for Neurology and Neurosurgery in London, is one of the principal investigators involved in the Athersys MASTERS-2 clinical trial, evaluating MultiStem…
Read More »Dr. Thorsten Döppner, Neurologist and Professor, and Dr. Beschan Ahmad, Sub-PI, at Universitaetsmedizin Goettingen – Georg-August-Universitaet discuss the Athersys MASTERS-2 clinical trial evaluating MultiStem cell therapy for the treatment of…
Read More »Five key opinion leaders (KOLs) in the field of stroke and a statistician to share their perspectives on the topline data from the TREASURE study conducted by the Athersys’ partner…
Read More »Clip courtesy of Fox32 in Chicago. Athersys, Inc. is developing MultiStem® cell therapy and is currently in late-stage clinical trials for ischemic stroke, ARDS, and trauma. The MASTERS-2 study is…
Read More »Trauma is the leading cause of death in people aged 1 to 44 and the leading cause of life years lost. Athersys is collaborating with The University of Texas Health…
Read More »Dr. Eric Jenkins, Senior Medical Director and Head of Clinical Programs at Athersys explains why the Company has chosen to focus on developing MuliStem® Cell Therapy for critical care indications.…
Read More »Athersys is a clinical late-stage regenerative medicine company developing MultiStem® (invimestrocel) cell therapy. This investor presentation provides an in-depth look at the its current clinical programs in ischemic stroke, acute…
Read More »Dr. Eric Jenkins, Senior Medical Director and Head of Clinical Programs at Athersys discusses the results of the MUST-ARDS clinical trial, evaluating MultiStem® Cell Therapy for the treatment of ARDS.…
Read More »Dr. Alice Valentin-Torres of Athersys discusses the research and findings described in the Scientific Reports by Nature publication supporting the hypothesis of how MAPC® (MultiStem®) modulates immune responses under different…
Read More »- 1
- 2